Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Trial
Official title:
Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
Verified date | July 2022 |
Source | UCB Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate the safety and efficacy of zilucoplan (RA101495) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.
Status | Completed |
Enrollment | 26 |
Est. completion date | March 28, 2018 |
Est. primary completion date | March 28, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of PNH by flow cytometry - For treatment naive patients: subjects must not have received treatment with eculizumab prior to or during the Screening Period and must have a lactate dehydrogenase (LDH) level =2 times the upper limit of normal (xULN) during Screening - For patients who previously received eculizumab: subjects must have received treatment with eculizumab for at least 6 months prior to Screening Exclusion Criteria: - History of meningococcal disease - Current systemic infection or suspicion of active bacterial infection |
Country | Name | City | State |
---|---|---|---|
Australia | Investigative Site | Gosford | New South Wales |
Australia | Investigative Site | Parkville | |
Canada | Investigative Site | Toronto | Ontario |
Denmark | Investigative Site | Copenhagen | |
Finland | Investigative Site | Helsinki | |
Germany | Investigative Site | Essen | |
Germany | Investigative Site | Ulm | |
Hungary | Investigative Site | Budapest | |
New Zealand | Investigative Site | Christchurch | |
New Zealand | Investigative Site | Hamilton | |
United Kingdom | Investigative Site | Leeds | |
United Kingdom | Investigative Site | London |
Lead Sponsor | Collaborator |
---|---|
Ra Pharmaceuticals |
Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level. | The primary efficacy endpoint is the change-from-baseline in serum LDH levels during this period, defined as the mean LDH values of Weeks 6, 8, 10, and 12 minus the baseline value of LDH. | Through Week 12 of the study | |
Secondary | Changes From Baseline in Bilirubin Values | Changes from baseline at each of the scheduled post-baseline time-points | Through Week 12 of the study | |
Secondary | Total Hemoglobin | Changes from baseline at each of the scheduled post-baseline time-points | Through Week 12 of the Study | |
Secondary | Changes From Baseline in Free Hemoglobin Values | Changes from baseline at each of the scheduled post-baseline time-points | Through Week 12 of the study | |
Secondary | Haptoglobin Values | Changes from baseline at each of the scheduled post-baseline time-points | Through Week 12 of the Study | |
Secondary | Reticulocyte Values | Changes from baseline at each of the scheduled post-baseline time-points | Through Week 12 of the Study | |
Secondary | Hemoglobinuria Values | Changes from baseline at each of the scheduled post-baseline time-points; Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria. | Through Week 12 of the Study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Terminated |
NCT05116787 -
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
|
Phase 2 | |
Recruiting |
NCT06294301 -
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT03472885 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
|
Phase 2 | |
Completed |
NCT03946748 -
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Enrolling by invitation |
NCT03427060 -
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
|
Phase 2 | |
Completed |
NCT03053102 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Not yet recruiting |
NCT06312644 -
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
|
||
Completed |
NCT03588026 -
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
|
Phase 3 | |
Completed |
NCT03056040 -
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
|
Phase 3 | |
Completed |
NCT00145613 -
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00587054 -
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
|
Phase 2 | |
Recruiting |
NCT05876312 -
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
|
Phase 1 | |
Completed |
NCT04820530 -
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
|
Phase 3 | |
Terminated |
NCT03225287 -
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
|
Phase 2 | |
Completed |
NCT04558918 -
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
|
Phase 3 | |
Completed |
NCT02352493 -
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
|
Phase 1/Phase 2 | |
Recruiting |
NCT04901936 -
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT02264639 -
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
|
Phase 1 | |
Recruiting |
NCT03520647 -
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
|
Phase 2 |